JP7617029B2 - 前立腺がんおよびリンパ腫の染色体コンフォメーションマーカー - Google Patents

前立腺がんおよびリンパ腫の染色体コンフォメーションマーカー Download PDF

Info

Publication number
JP7617029B2
JP7617029B2 JP2021566070A JP2021566070A JP7617029B2 JP 7617029 B2 JP7617029 B2 JP 7617029B2 JP 2021566070 A JP2021566070 A JP 2021566070A JP 2021566070 A JP2021566070 A JP 2021566070A JP 7617029 B2 JP7617029 B2 JP 7617029B2
Authority
JP
Japan
Prior art keywords
chromosomal
dlbcl
markers
samples
interactions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021566070A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532108A5 (https=
JP2022532108A (ja
JPWO2020225551A5 (https=
Inventor
ハンター、ユアン
ラマダス、アロウル
アクーリチェフ、アレクサンドル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biodynamics PLC
Original Assignee
Oxford Biodynamics PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1906487.2A external-priority patent/GB201906487D0/en
Priority claimed from GB201914729A external-priority patent/GB201914729D0/en
Priority claimed from GBGB2006286.5A external-priority patent/GB202006286D0/en
Application filed by Oxford Biodynamics PLC filed Critical Oxford Biodynamics PLC
Publication of JP2022532108A publication Critical patent/JP2022532108A/ja
Publication of JP2022532108A5 publication Critical patent/JP2022532108A5/ja
Publication of JPWO2020225551A5 publication Critical patent/JPWO2020225551A5/ja
Priority to JP2024211835A priority Critical patent/JP2025032205A/ja
Application granted granted Critical
Publication of JP7617029B2 publication Critical patent/JP7617029B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113—PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/10—Detection mode being characterised by the assay principle
    • C12Q2565/101—Interaction between at least two labels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2021566070A 2019-05-08 2020-05-06 前立腺がんおよびリンパ腫の染色体コンフォメーションマーカー Active JP7617029B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024211835A JP2025032205A (ja) 2019-05-08 2024-12-04 前立腺がんおよびリンパ腫の染色体コンフォメーションマーカー

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1906487.2A GB201906487D0 (en) 2019-05-08 2019-05-08 DNA Marker
GB1906487.2 2019-05-08
GB1914729.7 2019-10-11
GB201914729A GB201914729D0 (en) 2019-10-11 2019-10-11 DNA marker
GB2006286.5 2020-04-29
GBGB2006286.5A GB202006286D0 (en) 2020-04-29 2020-04-29 DNA marker
PCT/GB2020/051105 WO2020225551A1 (en) 2019-05-08 2020-05-06 Chromosome conformation markers of prostate cancer and lymphoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024211835A Division JP2025032205A (ja) 2019-05-08 2024-12-04 前立腺がんおよびリンパ腫の染色体コンフォメーションマーカー

Publications (4)

Publication Number Publication Date
JP2022532108A JP2022532108A (ja) 2022-07-13
JP2022532108A5 JP2022532108A5 (https=) 2023-05-16
JPWO2020225551A5 JPWO2020225551A5 (https=) 2023-05-16
JP7617029B2 true JP7617029B2 (ja) 2025-01-17

Family

ID=70775424

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021566070A Active JP7617029B2 (ja) 2019-05-08 2020-05-06 前立腺がんおよびリンパ腫の染色体コンフォメーションマーカー
JP2024211835A Pending JP2025032205A (ja) 2019-05-08 2024-12-04 前立腺がんおよびリンパ腫の染色体コンフォメーションマーカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024211835A Pending JP2025032205A (ja) 2019-05-08 2024-12-04 前立腺がんおよびリンパ腫の染色体コンフォメーションマーカー

Country Status (14)

Country Link
US (1) US20230049379A1 (https=)
EP (1) EP3966350A1 (https=)
JP (2) JP7617029B2 (https=)
KR (1) KR20220007132A (https=)
CN (2) CN120591403A (https=)
AU (3) AU2020268861B2 (https=)
CA (1) CA3138719A1 (https=)
GB (3) GB2626699B (https=)
IL (1) IL287597A (https=)
MY (1) MY203765A (https=)
SG (1) SG11202112221TA (https=)
TW (1) TWI873135B (https=)
WO (1) WO2020225551A1 (https=)
ZA (1) ZA202109658B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202302862A (zh) * 2021-03-04 2023-01-16 英商牛津生物力學公眾有限公司 染色體交互作用標記物
WO2025215190A1 (en) * 2024-04-12 2025-10-16 Oxford BioDynamics PLC Method of typing chromosome markers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018100381A1 (en) 2016-12-01 2018-06-07 Oxford Biodynamics Limited Application of epigenetic chromsomal interactions in cancer diagnostics
JP2018527016A (ja) 2015-06-24 2018-09-20 オックスフォード バイオダイナミックス リミテッド 染色体相互作用の検出

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2704625A1 (en) * 2007-11-08 2009-05-14 University Of Washington Dna microarray based identification and mapping of balanced translocation breakpoints
US10364469B2 (en) * 2014-01-16 2019-07-30 Illumina, Inc Gene expression panel for prognosis of prostate cancer recurrence
WO2016193110A1 (en) * 2015-05-29 2016-12-08 Koninklijke Philips N.V. Methods of prostate cancer prognosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018527016A (ja) 2015-06-24 2018-09-20 オックスフォード バイオダイナミックス リミテッド 染色体相互作用の検出
WO2018100381A1 (en) 2016-12-01 2018-06-07 Oxford Biodynamics Limited Application of epigenetic chromsomal interactions in cancer diagnostics
JP2019535295A (ja) 2016-12-01 2019-12-12 オックスフォード バイオダイナミクス リミテッド がんの診断における後成的染色体相互作用の応用

Also Published As

Publication number Publication date
ZA202109658B (en) 2022-08-31
GB202117415D0 (en) 2022-01-19
TWI873135B (zh) 2025-02-21
AU2021286283A1 (en) 2022-01-06
CN114008218B (zh) 2025-06-06
US20230049379A1 (en) 2023-02-16
GB2597895B (en) 2024-09-11
TW202108773A (zh) 2021-03-01
WO2020225551A1 (en) 2020-11-12
KR20220007132A (ko) 2022-01-18
GB2597895A (en) 2022-02-09
GB2626699A (en) 2024-07-31
GB2626699B (en) 2024-11-20
AU2021286283B2 (en) 2022-04-07
JP2022532108A (ja) 2022-07-13
JP2025032205A (ja) 2025-03-11
IL287597A (en) 2021-12-01
AU2021286282A1 (en) 2022-01-06
AU2020268861A1 (en) 2021-11-25
AU2021286282B2 (en) 2022-04-07
MY203765A (en) 2024-07-17
SG11202112221TA (en) 2021-12-30
AU2020268861B2 (en) 2022-02-03
CN114008218A (zh) 2022-02-01
CA3138719A1 (en) 2020-11-12
GB202406403D0 (en) 2024-06-19
CN120591403A (zh) 2025-09-05
EP3966350A1 (en) 2022-03-16

Similar Documents

Publication Publication Date Title
JP7297015B2 (ja) エピジェネティックな染色体相互作用
JP7631400B2 (ja) 遺伝子調節
JP2025032205A (ja) 前立腺がんおよびリンパ腫の染色体コンフォメーションマーカー
EP4320618A2 (en) Cell-free dna sequence data analysis method to examine nucleosome protection and chromatin accessibility
JP2021526375A (ja) 検出方法
US20260002208A1 (en) Chromosome interactions
JP2025108590A (ja) 診断用染色体マーカー
ES3029416T3 (en) Chromosome interaction markers
JPWO2020225551A5 (https=)
Hayward et al. The role of DNA methylation in stratifying and understanding nephrotic syndrome
CN117795098A (zh) 染色体相互作用标志物
WO2024118500A2 (en) Methods for detecting and treating ovarian cancer

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230502

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250106

R150 Certificate of patent or registration of utility model

Ref document number: 7617029

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150